Forward to: Commercial Team

Commercial & Market
Access Workflows

Ten agent workflows for the Commercial Team -- payer landscape monitoring, formulary decision tracking, pricing intelligence, HTA assessment analysis, patient access program tracking, specialty pharmacy intelligence, competitive launch monitoring, market share estimation, rebate and contracting intelligence, and commercial dashboard -- enabling data-driven market access strategy powered by comprehensive domain intelligence.

These workflows display realistic demo data for demonstration. In production, the agents connect to your real pharmaceutical data via MCP services or CSV import.
Deployment Options
The entire platform is available as a self-hosted solution or managed service
Self-Hosted
RECOMMENDED FOR ENTERPRISE
Deploy the entire platform on your own infrastructure. Your data never leaves your environment. Bring your own LLM API key (OpenAI, Claude, Gemini) or use local LLMs. Full source code delivered.
Complete source code (Python agents, PHP dashboards, MCP services)
Data stays on your servers — no external data transfer
MCP connectors for clinical trial, regulatory, and research databases
Custom integration and onboarding support available
$999
2 AI Agents
5 integration hrs
$1,999
5 AI Agents
10 integration hrs
$3,999
10 AI Agents
20 integration hrs
one-time license + (optional) $999/yr updates
Managed Platform
FOR AGENCIES & TEAMS
We host and operate the platform for you. Upload data or connect your platforms via secure MCP services or using API. No infrastructure management needed.
Fully managed — no DevOps required on your side
Secure data upload or API-based MCP integration
Dashboard access with your own branded login
Automatic updates and new agent releases
$999/mo
2 AI Agents
5 integration hrs
$1,999/mo
5 AI Agents
10 integration hrs
$3,999/mo
10 AI Agents
20 integration hrs
includes hosting, updates & support
* price may be higher in cases of very high AI processing volumes/demands
Both options include MCP services with connectors for clinical trial, regulatory, and research databases. Data dictionaries define the schema contract between each agent and your data sources.
See example of production dashboards: Programmatic Trading AI Agent Dashboards →

1Payer Landscape Monitoring

AI agent monitors health insurance company domains, PBM portals, and Medicaid agency pages to track payer policy changes, coverage decisions, and utilization management updates.

1
Track Payer Policy Changes
/products/press/complianceOpenPageRank
PAYER LANDSCAPE INTELLIGENCE — OBESITY ════════════════════════════════════════════════════════ COMMERCIAL PAYERS: unitedhealthgroup.com (UHC/Optum) /products: GLP-1 coverage expanded — prior auth simplified Policy: BMI 30+ or 27+ with comorbidities SIGNAL: Largest payer opening access — market expansion cigna.com (Express Scripts) /products: Step therapy required — lifestyle program first Policy: 6-month documentation requirement SIGNAL: Cost containment via step therapy — access barrier aetna.com (CVS Caremark) /products: Preferred brand only — excluded competitors SIGNAL: Exclusive formulary deal — competitive lockout risk MEDICARE/MEDICAID: CMS: Medicare obesity coverage expansion — IRA provisions State Medicaid: 14 states covering GLP-1 for obesity (up from 8) COVERAGE TREND: Commercial payer GLP-1 coverage expanding 40% YoY

2Formulary Decision Tracking

AI agent monitors PBM formulary updates, P&T committee decisions, and tier placement changes that directly impact prescription volume and market share for competitive products.

1
Track Formulary Changes
/products/press/docsOpenPageRank
FORMULARY DECISION INTELLIGENCE — 2026 ════════════════════════════════════════════════════════ PBM FORMULARY UPDATES: express-scripts.com (ESI) /products: 2026 National Preferred Formulary update Added: Tirzepatide (Preferred) Removed: Semaglutide injection (Non-preferred) SIGNAL: ESI exclusive deal with Lilly — Novo market share at risk caremark.com (CVS) /products: 2026 formulary published Added: Semaglutide (Preferred) Removed: Tirzepatide (Non-preferred) SIGNAL: CVS counter-deal with Novo — market splitting by PBM optumrx.com /products: Preferred drug list update Both GLP-1s on formulary — open access TIER PLACEMENT ANALYSIS: Tier 2 (Preferred brand): Best access — lowest copay Tier 3 (Non-preferred): 30-40% utilization reduction Tier 5 (Specialty): Prior auth + step therapy — 50% lower fills

3Drug Pricing Intelligence

AI agent monitors WAC pricing, net price estimates, rebate signals, and pricing strategy shifts from competitor investor presentations and pricing pages.

1
Track Competitive Pricing
/pricing/investors/pressOpenPageRank
DRUG PRICING INTELLIGENCE — GLP-1 CLASS ════════════════════════════════════════════════════════ WAC PRICING COMPARISON: Semaglutide 2.4mg (Wegovy): $1,349/month WAC Tirzepatide (Zepbound): $1,059/month WAC Orforglipron (if approved): Est. $500-700/month — oral advantage NET PRICE SIGNALS (from investor pages): novonordisk.com: /investors — "US net price -12% YoY" SIGNAL: Aggressive rebating to maintain formulary position lilly.com: /investors — "Net price stability maintained" SIGNAL: Lower WAC strategy reducing need for rebates IRA PRICING IMPACT: Medicare negotiation candidates (2028): 15 drugs selected bms.com: Eliquis — Negotiated price 38% below WAC jnj.com: Stelara — Negotiated price 42% below WAC SIGNAL: IRA negotiation driving pre-emptive price competition GLOBAL PRICING: EU average: 45% below US WAC Japan: Biennial repricing — NHI cuts averaging 7%

4HTA Assessment Analysis

AI agent monitors health technology assessment outcomes from NICE, ICER, CADTH, and other HTA bodies to assess reimbursement likelihood and value-based pricing benchmarks.

1
Analyze HTA Outcomes
/press/investors/productsOpenPageRank
HTA ASSESSMENT INTELLIGENCE ════════════════════════════════════════════════════════ NICE (UK): Tirzepatide (obesity): Recommended — cost-effective at NHS price Lecanemab (Alzheimer's): Not recommended — ICER too high SIGNAL: NICE rejects Alzheimer's antibodies — UK access blocked ICER (US): GLP-1 obesity class review published Semaglutide: $1,349/mo vs ICER threshold $800-900/mo SIGNAL: ICER assessment gives payers leverage for rebate demands CADTH (Canada): Dupixent (COPD): Recommended with conditions Conditions: Price reduction required, restricted to eosinophilic COPD G-BA (Germany): Additional benefit ratings Q1: Considerable benefit: 4 products Minor benefit: 6 products No additional benefit: 3 products SIGNAL: G-BA benefit ratings tightening — price negotiation harder

5Patient Access Program Tracking

AI agent monitors copay assistance programs, free drug programs, and patient support services from competitor domains to benchmark patient access strategies and identify coverage gaps.

1
Benchmark Patient Access Programs
/products/support/pressOpenPageRank
PATIENT ACCESS PROGRAM INTELLIGENCE ════════════════════════════════════════════════════════ COPAY ASSISTANCE BENCHMARKS: lilly.com: Zepbound copay card /support: $0 copay for eligible commercial patients /products: Direct-to-patient LillyDirect program at $499/mo SIGNAL: Bypassing PBMs — direct patient pricing model novonordisk.com: Wegovy Savings Offer /support: Pay as low as $0 for 3 months /press: NovoCare expanded to include pharmacy navigation SIGNAL: Enhanced patient support to counter formulary exclusions FREE DRUG PROGRAMS: pfizer.com: Pfizer Patient Assistance /support: Income threshold raised to 400% FPL SIGNAL: Broadening free drug access ahead of IRA changes EMERGING MODELS: Subscription pricing: Lilly, Novo testing monthly subscription Outcomes-based contracts: 4 payers now requiring outcomes guarantees TREND: Direct-to-patient models disrupting traditional PBM channels

6Specialty Pharmacy Intelligence

AI agent monitors specialty pharmacy networks, distribution channel changes, and limited distribution drug arrangements that affect product access and market penetration.

1
Track Specialty Pharmacy Dynamics
/products/press/partnersOpenPageRank
SPECIALTY PHARMACY INTELLIGENCE ════════════════════════════════════════════════════════ SPECIALTY PHARMACY MARKET: cvsspecialty.com /products: Added 34 new specialty drugs in 2026 /press: Biosimilar auto-substitution program launched SIGNAL: CVS aggressive on biosimilar conversion optumrx.com /products: Specialty pharmacy integration with Optum clinics SIGNAL: Vertical integration — payer-pharmacy-clinic model accredohealth.com (ESI specialty) /products: Gene therapy dispensing capability added LIMITED DISTRIBUTION: Cell/gene therapies: Average 8 authorized centers per product Oncology specialty: LDD networks tightening — 12 pharmacies avg WHITE BAGGING vs BROWN BAGGING: 42% of payers now requiring white bagging for provider-admin drugs SIGNAL: Provider buy-and-bill model under pressure — margin impact TREND: Specialty drug spending now 55% of total pharma — growing 12% YoY

7Competitive Launch Monitoring

AI agent tracks competitor product launch activities including pre-launch promotional signals, sales force deployment, and market preparation activities detected from domain content changes.

1
Monitor Launch Readiness Signals
/products/press/careersOpenPageRank
COMPETITIVE LAUNCH INTELLIGENCE ════════════════════════════════════════════════════════ IMMINENT LAUNCHES (60-day window): lilly.com: Orforglipron (oral GLP-1) /careers: +800 obesity sales reps posted /products: HCP portal and patient website launched /press: KOL speaker bureau assembled SIGNAL: Full commercial infrastructure deployed — launch imminent astrazeneca.com: Dato-DXd (NSCLC) /careers: +200 oncology account managers /products: Treatment site finder page live SIGNAL: Commercial readiness confirmed PRE-LAUNCH SIGNALS: amgen.com: MariTide (obesity, monthly dosing) /careers: Obesity franchise head recruited — 12-18 month signal /press: Phase III enrollment ongoing — launch est. H2 2027 LAUNCH PERFORMANCE TRACKING: Wegovy (12 months post-launch): $6.2B revenue Zepbound (12 months post-launch): $4.8B revenue BENCHMARK: Top obesity launches reaching $5B+ in Year 1

8Market Share Estimation

AI agent estimates market share dynamics by analyzing investor-disclosed revenue data, prescription volume signals, and relative promotional intensity across competitive products.

1
Estimate Market Share Dynamics
/investors/press/productsOpenPageRank
MARKET SHARE INTELLIGENCE — OBESITY CLASS ════════════════════════════════════════════════════════ GLP-1 OBESITY MARKET SHARE (US, by revenue): novonordisk.com: Wegovy /investors: $6.2B trailing 12M — 52% share Trend: Declining from 68% — Zepbound pressure lilly.com: Zepbound /investors: $4.8B trailing 12M — 40% share Trend: Growing rapidly — supply constraints easing Other (compounding, off-label): 8% share — regulatory risk IMMUNOLOGY MARKET SHARE SHIFT: Humira (+ biosimilars): 38% → 22% (biosimilar erosion) Dupixent: 12% → 18% (new indications driving growth) Skyrizi: 8% → 14% (fastest growing IL-23) Rinvoq: 5% → 9% (expanding despite JAK concerns) Total obesity market: $12B (2026) — projected $50B+ by 2030 SIGNAL: Market share volatile — formulary wins driving 10-15% swings

9Rebate & Contracting Intelligence

AI agent analyzes rebate signals from investor disclosures, gross-to-net spreads, and contracting strategy shifts that indicate competitive pricing pressure and payer negotiation dynamics.

1
Analyze Rebate Dynamics
/investors/press/complianceOpenPageRank
REBATE & CONTRACTING INTELLIGENCE ════════════════════════════════════════════════════════ GROSS-TO-NET SPREAD ANALYSIS: novonordisk.com: /investors Semaglutide: WAC $1,349 | Est. net: $580 (57% GTN spread) SIGNAL: Deep rebating to maintain formulary access lilly.com: /investors Tirzepatide: WAC $1,059 | Est. net: $750 (29% GTN spread) SIGNAL: Lower WAC strategy preserving net revenue abbvie.com: /investors Humira: WAC $7,200/mo | Est. net: $2,400 (67% GTN spread) SIGNAL: Extreme rebating to defend against biosimilars PBM CONTRACTING TRENDS: Exclusive formulary deals: Increasing — 34% of categories Outcomes-based contracts: Growing — 12% of specialty drugs Value-based arrangements: $8B in VBA contracts active IRA IMPACT ON REBATING: Medicare rebate cap at inflation rate — excess penalties SIGNAL: Companies pre-positioning pricing below inflation threshold

10Commercial Intelligence Dashboard

AI agent synthesizes all commercial and market access intelligence into a consolidated dashboard tracking payer dynamics, pricing trends, formulary status, and competitive launch activity.

1
Synthesize Commercial Intelligence
/investors/press/products/pricingOpenPageRank
COMMERCIAL INTELLIGENCE DASHBOARD — Q1 2026 ════════════════════════════════════════════════════════ MARKET ACCESS OVERVIEW: Products tracked: 847 across 42 therapeutic areas Formulary changes detected: 234 this quarter Payer policy updates: 156 this quarter PRICING TRENDS: Average WAC increase: +4.8% (below CPI) Net price change: -2.3% (rebate pressure) IRA negotiation impact: -38% average for selected drugs LAUNCH TRACKER: Competitive launches next 6 months: 14 NMEs expected Highest impact: Orforglipron, Dato-DXd, Iptacopan Launch readiness signals detected: 8 products showing deployment STRATEGIC SIGNALS: Direct-to-patient models gaining traction — PBM disruption Biosimilar erosion accelerating — 40% price reduction in Year 1 GTN spreads widening across mature brands — margin pressure

Agent Comparison Table

All ten AI agents deployed for commercial and market access intelligence.

Agent NamePurposeDescriptionKey Outputs
Payer MonitorCoverage IntelMonitors payer domains for policy changes, coverage decisions, and utilization management updatesPolicy change alerts, coverage maps, UM requirement tracking
Formulary TrackerTier PlacementTracks PBM formulary updates, P&T decisions, and tier placement changesFormulary alerts, tier maps, exclusion tracking
Price AnalystPricing IntelMonitors WAC pricing, net price signals, and pricing strategy shifts from investor pagesPrice benchmarks, GTN estimates, IRA impact analysis
HTA TrackerValue AssessmentMonitors NICE, ICER, CADTH, and G-BA assessment outcomes and methodologiesHTA outcome alerts, value thresholds, reimbursement forecasts
Patient Access ScoutSupport ProgramsTracks copay programs, free drug initiatives, and patient support servicesProgram benchmarks, access gap analysis, enrollment metrics
Specialty Pharma MonitorDistributionMonitors specialty pharmacy networks and limited distribution arrangementsNetwork maps, distribution alerts, channel analysis
Launch TrackerCompetitive LaunchDetects launch preparation signals from careers, products, and promotional pagesLaunch readiness scores, deployment alerts, performance benchmarks
Share EstimatorMarket PositionEstimates market share from investor-disclosed revenue and promotional signalsShare estimates, trend analysis, competitive shift alerts
Rebate AnalystContracting IntelAnalyzes GTN spreads, rebate signals, and contracting strategy from investor disclosuresGTN estimates, rebate trends, VBA tracking
Commercial DashboardSynthesisAggregates all commercial intelligence into executive dashboardsQuarterly commercial briefs, market access maps, pricing reports

Frequently Asked Questions

How do agents track payer formulary changes?
Agents monitor PBM and health insurer domains for formulary list updates, tier placement changes, and prior authorization requirement modifications. When a competitor product is added, removed, or repositioned on a formulary, agents detect the change from product listing pages and policy update documents.
Can domain intelligence estimate drug net pricing?
While exact net prices are confidential, agents analyze investor page disclosures including gross-to-net adjustments, rebate accrual percentages, and revenue per unit metrics to estimate net pricing. Combined with WAC data from product pages, these signals provide directional net price intelligence.
How does competitive launch detection work?
Agents monitor multiple domain signals including careers page hiring surges for sales representatives, product page launches for HCP and patient portals, press releases for KOL engagements, and support page updates for access programs. The convergence of these signals indicates launch readiness 30-60 days before commercial availability.
What market share signals are available from domain intelligence?
Investor pages disclose revenue by product, growth rates, and market share estimates during earnings presentations. Combined with prescription volume signals from promotional intensity and launch trajectory comparisons, agents provide reasonably accurate market share estimates with quarterly update frequency.
How does the system track IRA drug pricing negotiation impacts?
Agents monitor CMS portal updates for selected drug lists, negotiated price announcements, and manufacturer response strategies from investor and press pages. The IRA's inflation rebate provisions and Part D redesign impacts are tracked through payer policy updates and manufacturer pricing adjustment signals.

Top 10 Ways AI Agents Transform Pharmaceutical Commercial Intelligence

1

Real-Time Formulary Change Detection

Agents detect formulary additions, exclusions, and tier changes from PBM domains before competitive impacts materialize, enabling proactive market access response.

2

Net Price Intelligence

Investor page analysis reveals gross-to-net dynamics that signal competitive pricing pressure and inform rebate strategy development.

3

Competitive Launch Early Warning

Multi-signal detection from career, product, and press pages identifies competitor launch readiness 30-60 days before commercial availability.

4

HTA Outcome Tracking

Monitoring NICE, ICER, and G-BA assessments provides value-based pricing benchmarks and reimbursement likelihood assessments globally.

5

Patient Access Benchmarking

Competitor copay program and patient support tracking reveals access strategies that can be benchmarked and improved upon.

6

Specialty Distribution Monitoring

Tracking specialty pharmacy networks and limited distribution arrangements ensures visibility into competitive channel strategies.

7

Market Share Trend Analysis

Quarterly market share estimation from investor disclosures enables competitive response to share shifts before they become entrenched.

8

Rebate Strategy Intelligence

GTN spread analysis from investor pages reveals competitive rebating intensity and informs contracting strategy development.

9

IRA Compliance Monitoring

Automated tracking of Medicare negotiation impacts and inflation rebate provisions ensures pricing strategy compliance and competitive awareness.

10

Unified Commercial Dashboard

Consolidated market access intelligence replaces fragmented payer tracking with real-time, domain-sourced visibility into competitive commercial dynamics.

Get the AI Agent Database
Get in Touch

Interested in AI Agent Domain Intelligence?

For pricing, subscription options, custom database builds, or enterprise partnerships — contact us below.

Power Your Pharma AI Agents with Domain Intelligence

Subscribe to the AI Agent Domain Database — continuous access to 102M domains, 20 page types each, quarterly refreshes, and real-time change signals for pharmaceutical competitive intelligence.

AI Agent Database View Pricing

Annual subscription includes quarterly data refreshes, change detection alerts, and priority API access.